These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27506979)

  • 1. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
    Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
    Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
    Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
    Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes.
    Zhou ZQ; Ota S; Deng C; Akiyama H; Hurlin PJ
    Hum Mol Genet; 2015 Mar; 24(6):1764-73. PubMed ID: 25432534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of a Sox9-β-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II.
    Shung CY; Ota S; Zhou ZQ; Keene DR; Hurlin PJ
    Hum Mol Genet; 2012 Nov; 21(21):4628-44. PubMed ID: 22843502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
    Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
    Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
    Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
    Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
    Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
    Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
    Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
    Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.
    Iwata T; Li CL; Deng CX; Francomano CA
    Hum Mol Genet; 2001 Jun; 10(12):1255-64. PubMed ID: 11406607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias.
    Zheng C; Lin X; Xu X; Wang C; Zhou J; Gao B; Fan J; Lu W; Hu Y; Jie Q; Luo Z; Yang L
    EBioMedicine; 2019 Feb; 40():695-709. PubMed ID: 30685387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
    Yamashita A; Morioka M; Kishi H; Kimura T; Yahara Y; Okada M; Fujita K; Sawai H; Ikegawa S; Tsumaki N
    Nature; 2014 Sep; 513(7519):507-11. PubMed ID: 25231866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.
    Qi H; Jin M; Duan Y; Du X; Zhang Y; Ren F; Wang Y; Tian Q; Wang X; Wang Q; Zhu Y; Xie Y; Liu C; Cao X; Mishina Y; Chen D; Deng CX; Chang Z; Chen L
    Biochim Biophys Acta; 2014 Jul; 1843(7):1237-47. PubMed ID: 24657641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
    Khnykin D; Olsnes S
    Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
    Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
    Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular basis of achondroplasia, hypochondroplasia, and thanatophoric dysplasia].
    Moskalewski S; Hyc A; Osiecka-Iwan A; Strzelczyk P
    Chir Narzadow Ruchu Ortop Pol; 2000; 65(3):327-33. PubMed ID: 11057021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.
    Guo C; Degnin CR; Laederich MB; Lunstrum GP; Holden P; Bihlmaier J; Krakow D; Cho YJ; Horton WA
    Cell Signal; 2008 Aug; 20(8):1471-7. PubMed ID: 18485666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
    Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
    PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
    Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
    Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
    Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
    Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice.
    Kimura T; Bosakova M; Nonaka Y; Hruba E; Yasuda K; Futakawa S; Kubota T; Fafilek B; Gregor T; Abraham SP; Gomolkova R; Belaskova S; Pesl M; Csukasi F; Duran I; Fujiwara M; Kavkova M; Zikmund T; Kaiser J; Buchtova M; Krakow D; Nakamura Y; Ozono K; Krejci P
    Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.